AI assistant
REDCENTRIC PLC — Director's Dealing 2019
Sep 30, 2019
7875_dirs_2019-09-30_2e7e1bea-0807-47ef-b406-1c65d0c8b3a7.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0498O
Redcentric PLC
30 September 2019
Redcentric plc
("Redcentric" or the "Company")
Director/PDMR Shareholding, Issue of Equity and Total Voting Rights
Redcentric plc (AIM: RCN), announces that on 26 September 2019 it received a notification of exercise from Peter Brotherton, Chief Executive Officer, in relation to nil-cost share options over 161,905 ordinary shares of 0.1p each in the Company ("Ordinary Shares"), pursuant to the Company's 2016 Long Term Incentive Plan (the "Option Exercise"). Following the Option Exercise, Mr Brotherton sold 76,905 Ordinary Shares at a price of 85 pence per Ordinary Share on 27 September 2019, in order to cover the tax and national insurance liability associated with the Option Exercise.
As a result, Mr Brotherton holds 105,000 Ordinary Shares in the Company. In addition, Mr Brotherton holds 899,198 share options in the Company.
Accordingly, application has been made for the 161,905 new Ordinary Shares to be issued pursuant to the option exercise to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 4 October 2019.
Following Admission, the Company will have a total of 149,310,713 Ordinary Shares in issue with one voting right per share. There are 326,905 Ordinary Shares held in Treasury. For reporting under the FCA's Disclosure Guidance and Transparency Rules, shareholders should exclude any shares held in Treasury and should use the figure of 148,983,808 Ordinary Shares (the issued voting share capital) when determining if they are required to notify their interest, or a change of their interest in the Company.
Enquiries:
Redcentric plc
Peter Brotherton, Chief Executive Officer Via Tuchan
Dean Barber, Chief Financial Officer
Tulchan
James Macey White, Matt Low +44 (0)20 7353 4200
Numis Securities Limited - Nomad and Joint Broker +44 (0)20 7260 1000
Simon Willis / Oliver Hardy /
finnCap Limited - Joint Broker +44 (0)20 7220 0500
Stuart Andrews / Rhys Williams
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Peter Brotherton
2.
Reason for the Notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Redcentric plc
b)
LEI
213800FGYMMNE9OKFD14
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p
Identification code
RCN GB00B7TW1V39
b)
Nature of the transaction
- Exercise of options granted under the Redcentric plc 2017 Long Term Incentive Plan
- Sale of ordinary shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) | Date of transaction(s) |
| Nil cost | 161,905 options exercised | 26 September 2019 |
| 85p | 76,905 ordinary shares sold | 27 September 2019 |
d)
Aggregated information:
· Aggregated volume
· Price
See 4 (c) above
e)
Date of the transactions
See 4 (c) above
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHLLMMTMBTTTRL